GrB-Fc-SD1 / AbBC Therapies - LARVOL DELTA

Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B (AACR 2024) - "We developed a fusion protein (GrB-Fc-SD1) composed of GrB and containing SD1, a novel human single-domain antibody that uniquely targets Region III of the mesothelin glycoprotein. Research supported by H2Biologics. Research conducted, in part, by the Clayton Foundation for Research."

Tumor cell • Lung Cancer • Mesothelioma • Oncology • Ovarian Cancer • Solid Tumor • GZMB • MSLN